脑髓康方配合尤瑞克林治疗非溶栓急性期脑梗死临床观察

Efficacy observation of Naosuikang formula combined with Urinary Kallidinogenase on acute cerebral infarction of non-thrombolysis

目的：观察脑髓康方联合尤瑞克林注射液对非溶栓急性期脑梗死患者的临床疗效。方法：将符合诊断标准、纳入标准的126例患者,随机分为治疗组、对照组,按照研究方案进行2周治疗,治疗前后分别进行美国国立卫生院神经功能缺损评分（NIHSS）、日常生活活动能力（ADL）量表（Barthel指数）评分及Rakin评分（mRS）。结果：治疗组总有效率为89.39%（95%CI=81.96%~96.82%）,对照组为81.67%（95%CI=71.88%~91.46%）,两组综合疗效比较（u=0.906 9,P=0.364 5）,差异未达到显著性意义。与对照组治疗后比较,治疗组的神经功能NIHSS评分参数、Barthel指数参数、mRS评分参数均未达到性著性意义。结论：在常规药物治疗的基础上,采用脑髓康方治疗非溶栓急性期脑梗死患者的疗效优于应用传统辨证用药的证据不足,其收益为OR=0.53（95%CI=0.36~1.02）,NNT=13（95%CI=5.01~35.13）,但显示出优势。

Objective： To observe the clinical effect of Naosuikang formula combined with Urinary Kallidinogenase on acute cerebral infarction of non-thrombolysis. Methods： 126 patients conforming to the research standards were randomly divided into treatment group and control group,and treated for 2 weeks according to research program. The scores of National Institute of Health stroke scale（ NIHSS）,Activities of Daily Living（ ADL） scale（ Barthel index） and modified Rakin scale（ mRS） were recorded respectively before and after treatment. Results：The total effective rate in treatment group was 89. 39%（ 95% CI = 81. 96% ~ 96. 82%）,while that in control group was 81. 67%（ 95% CI = 71. 88% ~ 91. 46%）. Compared the comprehensive effects of two groups（ u =0. 906 9,P = 0. 364 5）,the difference was not statistically significant. Compared with control group after treatment,the parameters of NIHSS score,Barthel index and mRS score in treatment group were not statistically significant. Conclusions： The evidence that the effect of Naosuikang formula combined with conventional medicines on acute cerebral infarction of non-thrombolysis is better than application of traditional TCM drugs is not enough. Its benefit is OR = 0. 53（ 95% CI = 0. 36 ~ 1. 02）,NNT = 13（ 95% CI = 5. 01 ~ 35. 13）. But it has shown the superiority.